Literature DB >> 22899034

Depression in Parkinson's disease: diagnosis and treatment.

Flavio Henrique de Rezende Costa1, Ana Lucia Zuma Rosso, Henryk Maultasch, Denise Hack Nicaretta, Maurice Borges Vincent.   

Abstract

The prevalence of non-motor symptoms in Parkinson's disease (PD) is high. Depression varies from 20 to 50% of the PD patients, and is associated with increasing disability. The key characteristics of depression are anhedonia and low mood. The recommended scales for screening purposes are: HAM-D, BDI, HADS, MADRS and GDS. As for measurement of severity: HAM-D, MADRS, BDI and SDS. In cases with mild depression, non-pharmacological intervention is the treatment of choice. In moderate depression, antidepressants are required. The choice of an antidepressant should be based mainly on the comorbidities and unique features of the patient. Evidence for antidepressant effectiveness is seen mostly with amitriptyline and nortriptyline, but one should be cautious in elderly patients. Other antidepressants that can be prescribed are: citalopram, escitalopram, sertraline, bupropion, trazodone, venlafaxine, mirtazapine and duloxetin. The dopaminergic agonist pramipexole is a treatment option.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22899034     DOI: 10.1590/s0004-282x2012000800011

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  18 in total

Review 1.  Detecting depression in Parkinson disease: A systematic review and meta-analysis.

Authors:  Zahra Goodarzi; Kelly J Mrklas; Derek J Roberts; Nathalie Jette; Tamara Pringsheim; Jayna Holroyd-Leduc
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

2.  Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-12

3.  Sleep and affective disorders in relation to Parkinson's disease risk among older women from the Women's Health Initiative.

Authors:  Hind A Beydoun; Jiu-Chiuan Chen; Nazmus Saquib; Michelle J Naughton; May A Beydoun; Aladdin H Shadyab; Lauren Hale; Alan B Zonderman
Journal:  J Affect Disord       Date:  2022-06-22       Impact factor: 6.533

Review 4.  Depressive symptoms in neurodegenerative diseases.

Authors:  Miquel Baquero; Nuria Martín
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337

5.  Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-08

6.  The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease.

Authors:  Gianfranco Spalletta; Robert G Robinson; Luca Cravello; Francesco E Pontieri; Mariangela Pierantozzi; Alessandro Stefani; Jeffrey D Long; Carlo Caltagirone; Francesca Assogna
Journal:  J Neurol       Date:  2014-04-03       Impact factor: 4.849

7.  Analysis of pramipexole dose-response relationships in Parkinson's disease.

Authors:  Ying Wang; Sheng-Gang Sun; Sui-Qiang Zhu; Chun-Feng Liu; Yi-Ming Liu; Qing Di; Hui-Fang Shang; Yan Ren; Wei Xiang; Sheng-Di Chen
Journal:  Drug Des Devel Ther       Date:  2016-12-23       Impact factor: 4.162

8.  Decrease of gene expression of astrocytic 5-HT2B receptors parallels development of depressive phenotype in a mouse model of Parkinson's disease.

Authors:  Xique Zhang; Dan Song; Li Gu; Yan Ren; Alexei Verkhratsky; Liang Peng
Journal:  Front Cell Neurosci       Date:  2015-10-06       Impact factor: 5.505

9.  Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.

Authors:  Naoto Kadoguchi; Shinji Okabe; Yukio Yamamura; Misaki Shono; Tatsuya Fukano; Akie Tanabe; Hironori Yokoyama; Jiro Kasahara
Journal:  BMC Neurosci       Date:  2014-06-25       Impact factor: 3.288

Review 10.  Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review.

Authors:  Marie Grall-Bronnec; Anne Sauvaget; Fanny Perrouin; Juliette Leboucher; François Etcheverrigaray; Gaëlle Challet-Bouju; Louise Gaboriau; Pascal Derkinderen; Pascale Jolliet; Caroline Victorri-Vigneau
Journal:  J Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.